04, 2025 (GLOBE NEWSWIRE) -- Noom, the leading digital healthcare company committed to chronic disease prevention and empowering people to live better longer, today announced the launch of the Noom Microdose GLP-1Rx Program, a groundbreaking offering designed to unlock weight loss and long-term health benefits while minimizing side effects through personalized microdoses of GLP-1 medication, when clinically appropriate
Their analysis found that GLP-1 users reported chronic cough roughly 29% more often than patients taking DPP-4 inhibitors, SGLT2 inhibitors, or sulfonylureas
The Medicare GLP-1 Bridge provides eligible patients access to Wegovy specifically for weight management
So in that 25 years, using frameworks like the phenotypes that you've actually studied, how much success were you able to have with lifestyle-focused treatments
Headaches occur in about 10% to 15% of users, most commonly during the first two weeks
Semaglutide (the active in Ozempic and Wegovy) targets a single receptor pathway